Business Description
ADC Therapeutics is a Swiss-American biotech company focused on developing targeted cancer treatments using antibody drug conjugate technology. Its leading medicine, ZYNLONTA, has received regulatory approval in the United States, Europe, and China for treating certain types of aggressive blood cancer that have returned or stopped responding to prior treatment. The company is working to expand ZYNLONTA's use into earlier stages of disease and additional cancer types, both alone and in combination with other therapies. It is also advancing a broader pipeline of experimental treatments aimed at several other cancer targets.
